BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been given a $5.00 price target by stock analysts at Cantor Fitzgerald in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 70.94% from the company’s current price.

Other equities analysts have also issued research reports about the company. HC Wainwright set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Monday, July 17th. ValuEngine lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Piper Jaffray Companies set a $4.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Janney Montgomery Scott raised their price target on BioDelivery Sciences International from $3.00 to $4.00 and gave the stock a “fair value” rating in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. BioDelivery Sciences International has a consensus rating of “Buy” and an average target price of $4.29.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down 0.847% during mid-day trading on Thursday, reaching $2.925. The company’s stock had a trading volume of 1,199,021 shares. BioDelivery Sciences International has a 52 week low of $1.50 and a 52 week high of $3.60. The stock has a market capitalization of $162.26 million, a price-to-earnings ratio of 104.464 and a beta of 0.95. The company’s 50-day moving average is $2.95 and its 200-day moving average is $2.58.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.45 million. BioDelivery Sciences International had a return on equity of 14.64% and a net margin of 3.34%. The business’s revenue for the quarter was up 74.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.31) EPS. Equities analysts predict that BioDelivery Sciences International will post $0.12 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price Target” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/12/cantor-fitzgerald-analysts-give-biodelivery-sciences-international-inc-bdsi-a-5-00-price-target.html.

In other news, CEO Mark A. Sirgo sold 24,516 shares of BioDelivery Sciences International stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $2.75, for a total transaction of $67,419.00. Following the completion of the sale, the chief executive officer now directly owns 1,509,262 shares in the company, valued at approximately $4,150,470.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Mark A. Sirgo sold 50,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $2.95, for a total transaction of $147,500.00. Following the sale, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at $4,452,322.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 402,127 shares of company stock valued at $1,142,798. 9.00% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the company. Valley National Advisers Inc. lifted its position in shares of BioDelivery Sciences International by 59.0% during the 2nd quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock valued at $106,000 after acquiring an additional 14,000 shares during the period. Cutter & CO Brokerage Inc. lifted its position in shares of BioDelivery Sciences International by 2.4% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 43,430 shares of the specialty pharmaceutical company’s stock valued at $122,000 after acquiring an additional 1,000 shares during the period. Advisor Group Inc. lifted its position in shares of BioDelivery Sciences International by 42.1% during the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after acquiring an additional 13,341 shares during the period. NEXT Financial Group Inc lifted its position in shares of BioDelivery Sciences International by 9.3% during the 2nd quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 4,000 shares during the period. Finally, Sterling Investment Management Inc. acquired a new stake in shares of BioDelivery Sciences International during the 2nd quarter valued at approximately $140,000. Institutional investors own 41.43% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.